Singapore Clinical Trial: A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by asciminib plus blinatumomab in pediatric, adolescent, and young adult participants with relapsed or refractory BCR::ABL1-positive (Philadelphia positive, Ph+) or BCR::ABL1-like (Ph-like) acute lymphoblastic leukemia (ALL)

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib wit... Read More

Singapore Clinical Trial: A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy... Read More

Singapore Clinical Trial: CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'CA2400030: A Randomized, Phase 2/3 Study Comparing Navlimetostat in Combination with Nab-paclitax... Read More

Singapore Clinical Trial: A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus Adjuvant Chemotherapy Versus Placebo Plus Adjuvant Chemotherapy in Stage IB-IIIA NSCLC Patients with Uncommon EGFR Mutations Following Complete Tumor Resection (REZILIENT4)

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Placebo-Controlled, Double-Blind, Multi-Center Phase 3 Study of Zipalertinib Plus A... Read More

Singapore Clinical Trial: Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations

Singapore, Sept. 17 -- The Health Sciences Authority received information related to the study titled 'Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvan... Read More

Apple executive Vivek Tiwari's killing by UP cop: Verdict in closely watched case expected today

India, Sept. 17 -- A district and sessions court will deliver its verdict Thursday in the case of Apple executive Vivek Tiwari shot dead by a police constable in Lucknow nearly eight years ago, closin... Read More

Dhaka ranks 19th among world's most polluted cities

Dhaka, Sept. 17 -- Dhaka ranked 19th among the world's most polluted cities on Thursday morning, recording an Air Quality Index (AQI) score of 93 at 10:30 am. The air quality was classified as 'Moder... Read More

'Speeding at over 100 km/h': Man crossing road with his birthday cake hit by car in Greater Noida

India, Sept. 17 -- A 32-year-old man was seriously injured after a speeding car allegedly hit him while he was crossing a road to collect his birthday cake in Greater Noida earlier this month. Recalli... Read More

New CRPF Headquarters with modern facilities likely to be ready by December 2026

India, Sept. 17 -- By Rajnish Singh New Delhi [India], September 17 (ANI): The Central Reserve Police Force (CRPF) is expected to make its new headquarters in the national capital operational by the ... Read More

Thales brings agentic AI to military command with HexaForce

New Delhi, Sept. 17 -- As modern military operations generate growing volumes of data from sensors, communications systems, cyber environments and other sources, artificial intelligence is beginning t... Read More

• ««
• «
• 3371
• 3372
• 3373
• 3374
• 3375
• 3376
• 3377
• 3378
• 3379
• 3380
• »
• »»